Employees at two polyurethane (68400679) manufacturing facilities were surveyed to determine the extent of urinary dysfunction due to dimethylaminopropionitrile (1738256) (DMAPN) exposure. Questionnaires were given to 141 workers at facility A and 75 workers at facility B to identify symptoms related to the skin, lungs, central nervous system, or urogenital system. All workers were given a complete physical examination, lung function tests, and blood and urine analyses. Workers with persistent symptoms of urinary retention were given intravenous pyelography tests. Symptoms of urinary retention among workers at both facilities included straining, hesitancy, decreased flow, intermittent flow, bladder distension, and the need for manual pressure to empty the bladder. Increased incidence of urinary retention, muscle weakness, paresthesia, insomnia, and sexual dysfunction also was found among exposed workers. Results of blood and urine analyses were normal. After removal of a catalytic agent containing DMAPN, no new cases were reported. The authors suggest that new and previously used chemicals should be studied for their potential toxicity in industrial use. Symptoms that an employee thinks may be work related should be thoroughly investigated.